Company: ANTX
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0000950170-25-052852
Chunk: 51

Company: AN2 Therapeutics, Inc.
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 51
---
------------------|:----|:--|--------:|:----|:--|----------:|
| Audit fees(1)     |     | $ | 752,000 |     | $ | 1,332,500 |
| Tax fees(2)       |     |   |  50,000 |     |   |    25,000 |
| All other fees(3) |     |   |   2,000 |     |   |     4,150 |
| Total fees        |     | $ | 804,000 |     | $ | 1,361,650 |

(1) Audit fees consist of fees billed for professional services performed by PricewaterhouseCoopers LLP for the audit of our annual financial statements, the review of interim financial statements, and related services that are normally provided in connection with registration statements. (2) Tax fees consist of recurring tax services. (3) All other fees include any fees billed that are not audit, audit-related, or tax fees. These fees related to accounting research software. All services described above were pre-approved by our audit committee. Policy on Audit Committee Pre-Approval of Audit and Permissible Non-Audit Services of Independent Registered Public Accounting Firm Pursuant to the audit committee charter and policy, the audit committee pre-approves all audit and permissible non-audit services to be provided by our independent registered public accounting firm. As part of its review, the audit committee also considers whether the categories of pre-approved services are consistent with the rules on accountant independence of the SEC and the Public Company Accounting Oversight Board. Recommendation of our Board The Board unanimously recommends a vote FOR the ratification of PricewaterhouseCoopers LLP as our independent registered public accounting firm for the year ending December 31, 2025.

<div align='center'>29

AUDIT COMMITTEE REPORT</div>

The information contained in the following Audit Committee Report shall not be deemed to be soliciting material or to be filed with the Securities and Exchange Commission, nor shall such information be incorporated by reference into any future filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that AN2 Therapeutics, Inc. (the “Company”) specifically incorporates it by reference in such filing.

The audit committee has reviewed and discussed the audited financial statements for the fiscal year ended December 31, 2024 with management of the Company. The audit committee has discussed with